Drugs that contain Cilastatin Sodium; Imipenem; Relebactam
1. List of Recarbrio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Nov, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 16, 2024 |
| Generating Antibiotic Incentives Now (GAIN) | Jul 16, 2029 |
NCE-1 date: July, 2028
Market Authorisation Date: 16 July, 2019
Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urinary tract infections, including pyelonephritis (cuti)
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic